Abstract
Recent studies have shown an activation of the local renin-angiotensin system (RAS) in various tumor tissues, including the abundant generation of angiotensin II (Ang II) by angiotensin-converting enzyme (ACE) and the upregulation of angiotensin II type 1 receptor (AT1R) expression. Thus, considerable attention has been paid not only to the role of the RAS in cancer progression, but also to the blockade of RAS as a new approach to the treatment of human cancer. There is increasing evidence that the Ang II-AT1R pathway is involved in tumor growth, angiogenesis and metastasis in various experimental animal models, suggesting the therapeutic potential of an ACE inhibitor and AT1R blocker. In addition, specific Ang II-degrading enzymes are also expressed in tumors and play a regulatory role in tumor cell proliferation and invasion. This review focuses on the role of the RAS in the progression of gynecologic cancers, such as cervical cancer, endometrial cancer, ovarian cancer, and gestational choriocarcinoma. We present here the clinical potential of blocking the RAS as a novel and promising strategy for the treatment of gynecologic cancers.
Keywords: Angiogenesis, Angiotensin II type 1 receptor, Cervical cancer, Endometrial cancer, Ovarian cancer, Reninangiotensin system (RAS), Survival, Vascular endothelial growth factor, Adipocyte-derived leucine aminopeptidase, Aminopeptidase A
Current Cancer Drug Targets
Title: Role of the Renin-Angiotensin System in Gynecologic Cancers
Volume: 11 Issue: 4
Author(s): K. Ino, K. Shibata, E. Yamamoto, H. Kajiyama, A. Nawa, Y. Mabuchi, S. Yagi, S. Minami, Y. Tanizaki, A. Kobayashi and F. Kikkawa
Affiliation:
Keywords: Angiogenesis, Angiotensin II type 1 receptor, Cervical cancer, Endometrial cancer, Ovarian cancer, Reninangiotensin system (RAS), Survival, Vascular endothelial growth factor, Adipocyte-derived leucine aminopeptidase, Aminopeptidase A
Abstract: Recent studies have shown an activation of the local renin-angiotensin system (RAS) in various tumor tissues, including the abundant generation of angiotensin II (Ang II) by angiotensin-converting enzyme (ACE) and the upregulation of angiotensin II type 1 receptor (AT1R) expression. Thus, considerable attention has been paid not only to the role of the RAS in cancer progression, but also to the blockade of RAS as a new approach to the treatment of human cancer. There is increasing evidence that the Ang II-AT1R pathway is involved in tumor growth, angiogenesis and metastasis in various experimental animal models, suggesting the therapeutic potential of an ACE inhibitor and AT1R blocker. In addition, specific Ang II-degrading enzymes are also expressed in tumors and play a regulatory role in tumor cell proliferation and invasion. This review focuses on the role of the RAS in the progression of gynecologic cancers, such as cervical cancer, endometrial cancer, ovarian cancer, and gestational choriocarcinoma. We present here the clinical potential of blocking the RAS as a novel and promising strategy for the treatment of gynecologic cancers.
Export Options
About this article
Cite this article as:
Ino K., Shibata K., Yamamoto E., Kajiyama H., Nawa A., Mabuchi Y., Yagi S., Minami S., Tanizaki Y., Kobayashi A. and Kikkawa F., Role of the Renin-Angiotensin System in Gynecologic Cancers, Current Cancer Drug Targets 2011; 11 (4) . https://dx.doi.org/10.2174/156800911795538057
DOI https://dx.doi.org/10.2174/156800911795538057 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Occurrence and Severity of Adverse Reactions of Immune Checkpoint
Inhibitors (PD-1 and PD L1) Based on Mordovian Dispensary Data
Analysis
Current Cancer Therapy Reviews A Computer-Based Approach to the Rational Discovery of New Trichomonacidal Drugs by Atom-Type Linear Indices
Current Drug Discovery Technologies Nucleo-Cytoplasmic Transport of Proteins as a Target for Therapeutic Drugs
Current Medicinal Chemistry Synthesis and Antitumor Activity Evaluation of New Phenanthrene-Based Tylophorine Derivatives
Letters in Organic Chemistry The Chemistry and Pharmacology of Genistein
The Natural Products Journal Valproic Acid in the Complex Therapy of Malignant Tumors
Current Drug Targets Iron Chelators in Cancer Chemotherapy
Current Topics in Medicinal Chemistry Dietary Agents for Prostate Cancer Chemoprevention: An Overview
Current Cancer Therapy Reviews Antimicrobial, In Vitro and In Vivo Antineoplastic Activities, Mechanism of Action, Structural and Thermal Properties of a Small-Novel Pharmaceutical Organometallic Chelate
Mini-Reviews in Medicinal Chemistry Dysregulation of Neurotrophic and Haematopoietic Growth Factors in Alzheimer’s Disease: From Pathophysiology to Novel Treatment Strategies
Current Alzheimer Research Development of Natural Bioactive Alkaloids: Anticancer Perspective
Mini-Reviews in Medicinal Chemistry Synthesis, Characterization, Anticancer and Antibacterial Activity of Some Novel Pyrano[2,3-d]pyrimidinone Carbonitrile Derivatives
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs in Lung Cancer and Lung Cancer Bone Metastases: Biomarkers for Early Diagnosis and Targets for Treatment
Recent Patents on Anti-Cancer Drug Discovery Neoplastic Conditions in the Context of HIV-1 Infection
Current HIV Research Effects of Epirubicin and Cisplatin Against 4T1 Breast Cancer Cells are Enhanced by Myrtucommulone-A
Anti-Cancer Agents in Medicinal Chemistry Diffuse Large B-Cell Lymphoma Presenting as an Anterior Chest Wall Mass: A Case Report and Literature Review
Current Respiratory Medicine Reviews Molecular and Clinical Analysis of Predictive Biomarkers in Non-Small-Cell Lung Cancer
Current Medicinal Chemistry The Nervous System as a Critical Regulator of Immune Responses Underlying Allergy
Current Pharmaceutical Design Magnetic Resonance Nano-Theranostics for Glioblastoma Multiforme
Current Pharmaceutical Design Perioperative B-blockers in Non-cardiac Surgery: Actual Situation
Current Pharmaceutical Design